MA45721A - Procédés de purification de protéines contenant des fragments fc - Google Patents

Procédés de purification de protéines contenant des fragments fc

Info

Publication number
MA45721A
MA45721A MA045721A MA45721A MA45721A MA 45721 A MA45721 A MA 45721A MA 045721 A MA045721 A MA 045721A MA 45721 A MA45721 A MA 45721A MA 45721 A MA45721 A MA 45721A
Authority
MA
Morocco
Prior art keywords
fragments
processes
protein containing
purifying protein
purifying
Prior art date
Application number
MA045721A
Other languages
English (en)
Inventor
John K Kawooya
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MA45721A publication Critical patent/MA45721A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/34—Size selective separation, e.g. size exclusion chromatography, gel filtration, permeation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G, L chromatography
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/42—Selective adsorption, e.g. chromatography characterised by the development mode, e.g. by displacement or by elution
    • B01D15/424—Elution mode
    • B01D15/426—Specific type of solvent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Water Supply & Treatment (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Storage Device Security (AREA)
MA045721A 2016-07-22 2017-07-21 Procédés de purification de protéines contenant des fragments fc MA45721A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662365943P 2016-07-22 2016-07-22

Publications (1)

Publication Number Publication Date
MA45721A true MA45721A (fr) 2019-05-29

Family

ID=59656168

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045721A MA45721A (fr) 2016-07-22 2017-07-21 Procédés de purification de protéines contenant des fragments fc

Country Status (12)

Country Link
US (1) US11312745B2 (fr)
EP (1) EP3487867A2 (fr)
JP (2) JP7092744B2 (fr)
KR (2) KR102579850B1 (fr)
CN (2) CN109563125B (fr)
AU (2) AU2017298984B2 (fr)
CA (2) CA3031469A1 (fr)
IL (2) IL285146B (fr)
MA (1) MA45721A (fr)
MX (2) MX2019000903A (fr)
SG (1) SG11201900573UA (fr)
WO (1) WO2018018011A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3113057A1 (fr) * 2018-09-21 2020-03-26 Teneobio, Inc. Methodes de purification d'anticorps heterodimeres multispecifiques
CA3114802A1 (fr) * 2018-10-11 2020-04-16 Amgen Inc. Traitement en aval de constructions d'anticorps bispecifiques
KR102286892B1 (ko) * 2019-07-08 2021-08-06 삼천당제약주식회사 안과용 단백질 제제의 정제방법
CN110724204B (zh) * 2019-11-18 2021-10-22 广东菲鹏制药股份有限公司 Fc融合蛋白的纯化方法
CN112881675A (zh) * 2019-11-29 2021-06-01 广东菲鹏生物有限公司 IgM抗体检测稀释液
US20220081468A1 (en) * 2020-09-16 2022-03-17 Waters Technologies Corporation Size exclusion chromatography utilizing low concentration amino acids in size exclusion chromatography mobile phase
AU2022369694A1 (en) * 2021-10-19 2024-05-30 Alteogen, Inc Method for purifying fusion protein having igg fc domain
CN113980092B (zh) * 2021-12-09 2024-05-14 上海药明生物技术有限公司 一种蛋白质亲和纯化方法
CN116271982B (zh) * 2022-11-30 2024-01-09 杭州广科安德生物科技有限公司 一种血液高丰度蛋白免疫亲和柱的再生方法

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
JP3068180B2 (ja) 1990-01-12 2000-07-24 アブジェニックス インコーポレイテッド 異種抗体の生成
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5350683A (en) 1990-06-05 1994-09-27 Immunex Corporation DNA encoding type II interleukin-1 receptors
WO1991018982A1 (fr) 1990-06-05 1991-12-12 Immunex Corporation Recepteurs de l'interleukine-1 de type ii
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
DE69637481T2 (de) 1995-04-27 2009-04-09 Amgen Fremont Inc. Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
KR20080059467A (ko) 1996-12-03 2008-06-27 아브게닉스, 인크. 복수의 ｖｈ 및 ｖｋ 부위를 함유하는 사람 면역글로불린유전자좌를 갖는 형질전환된 포유류 및 이로부터 생성된항체
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
CA2325022A1 (fr) * 1998-04-16 1999-10-21 Genentech, Inc. Secretion de proteines glycosylees au moyen d'une pro-sequence de l'activateur tissulaire du plasminogene
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
NZ554520A (en) 2004-10-22 2010-03-26 Amgen Inc Methods for refolding of recombinant antibodies
US7834162B2 (en) * 2006-01-06 2010-11-16 Amgen Inc. Methods and systems for isolating target molecules from complex solutions by column-chromatography using eluants containing organic solvents
CA2654317A1 (fr) 2006-06-12 2007-12-21 Trubion Pharmaceuticals, Inc. Proteines de liaison monocatenaires polyvalentes dotees d'une fonction d'effecteur
WO2008036600A2 (fr) * 2006-09-18 2008-03-27 Genentech, Inc. Procédés de production de protéines
WO2008143199A1 (fr) * 2007-05-21 2008-11-27 Nomadic Bioscience Co., Ltd. Nouveau polypeptide, matériel pour chromatographie d'affinité, et procédé de séparation et/ou de purification d'une immunoglobuline
HUE028536T2 (en) 2008-01-07 2016-12-28 Amgen Inc Method for producing antibody to FC heterodimer molecules using electrostatic control effects
JP5529869B2 (ja) * 2008-08-14 2014-06-25 メルク・シャープ・アンド・ドーム・コーポレーション プロテインａアフィニティークロマトグラフィーを用いる抗体の精製方法
EP3366692A1 (fr) 2009-06-22 2018-08-29 Amgen, Inc Repliement de protéines au moyen d' un état redox chimiquement régulé
EP2445924B2 (fr) 2009-06-25 2023-12-13 Amgen Inc. Procédés de purification par capture de protéines exprimées dans un système non mammifère
CA2781519A1 (fr) 2009-09-16 2011-03-24 Genentech, Inc. Complexes proteiques contenant une super-helice et/ou une attache et leurs utilisations
CN102382190B (zh) 2010-09-01 2014-04-09 山东新时代药业有限公司 分离和去除TNFR-Fc融合蛋白中寡聚体的方法
JPWO2012086837A1 (ja) 2010-12-24 2014-06-05 旭化成メディカル株式会社 温度応答性プロテインａの固定化方法
JP6280499B2 (ja) * 2011-07-08 2018-02-14 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｆｃ融合タンパク質の精製方法
WO2013147691A1 (fr) 2012-03-28 2013-10-03 Ge Healthcare Bio-Sciences Ab Matrice de chromatographie par affinité
JP6253584B2 (ja) 2012-08-27 2017-12-27 旭化成メディカル株式会社 温度応答性クロマトグラフィーによる抗体の精製方法
UY35148A (es) * 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
US20140302037A1 (en) 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
SG11201603244VA (en) * 2013-11-04 2016-05-30 Glenmark Pharmaceuticals Sa Production of t cell retargeting hetero-dimeric immunoglobulins

Also Published As

Publication number Publication date
CN115925780A (zh) 2023-04-07
IL285146A (en) 2021-08-31
KR20220120716A (ko) 2022-08-30
CN109563125B (zh) 2022-08-09
WO2018018011A2 (fr) 2018-01-25
AU2017298984B2 (en) 2023-08-31
JP2019528255A (ja) 2019-10-10
KR102579850B1 (ko) 2023-09-18
CA3218290A1 (fr) 2018-01-25
AU2023222915A1 (en) 2023-09-21
AU2017298984A1 (en) 2019-02-07
SG11201900573UA (en) 2019-02-27
JP7092744B2 (ja) 2022-06-28
MX2019000903A (es) 2019-05-15
IL264375B (en) 2021-09-30
CA3031469A1 (fr) 2018-01-25
JP2022120138A (ja) 2022-08-17
JP7411020B2 (ja) 2024-01-10
KR20190037247A (ko) 2019-04-05
US20190127418A1 (en) 2019-05-02
US11312745B2 (en) 2022-04-26
IL285146B (en) 2022-09-01
MX2023006291A (es) 2023-06-13
KR102435801B1 (ko) 2022-08-25
IL264375A (en) 2019-02-28
WO2018018011A3 (fr) 2018-03-01
CN109563125A (zh) 2019-04-02
EP3487867A2 (fr) 2019-05-29

Similar Documents

Publication Publication Date Title
MA45721A (fr) Procédés de purification de protéines contenant des fragments fc
MA39774A (fr) Procédés chimiques pour produire des nucléotides étiquetés
EP3408219A4 (fr) Appareil de séquençage d'adn massivement parallèle
MA41294A (fr) Anticorps anti-myostatine, polypeptides contenant des variants de régions fc, et procédés d'utilisation
EP3427824A4 (fr) Catalyseur pour purification de gaz d'échappement
FR3014901B1 (fr) Procede de purification de virus ou vecteurs viraux enveloppes
FR3025515B1 (fr) Procede de purification d'un anticorps monoclonal
IL261040B (en) Protein purification
MA41941A (fr) Procédé de purification de protéines
GB201705213D0 (en) Exhaust gas purification filter
EP3275543A4 (fr) Catalyseur de purification de gaz d'échappement
PL3513821T3 (pl) Materiał do oczyszczania krwi
EP3275544A4 (fr) Catalyseur de purification des gaz d'échappement
FR3039433B1 (fr) Methode d'epuration selective d'aerosols
EP3160611A4 (fr) Procédés et réactifs destinés à la purification de protéines
HUE055160T2 (hu) Eljárás klorid-tartalmú reakcióoldatok elektrokémiai tisztítására
EP3318533A4 (fr) Cuivre supporté sur zéolite et catalyseur de traitement de purification de gaz d'échappement contenant ladite zéolite
FR3021230B1 (fr) Procede de purification de nanofils metalliques
EP3438426A4 (fr) Système de purification d'échappement
FR2990878B1 (fr) Procede de purification de melanges gazeux contenant des gaz acides.
EP3341112A4 (fr) Procédés et compositions de purification de protéine et de mise en réaction d'une enzyme
MA41297A (fr) Système de purification de liquides
MA41961A (fr) Procédés de régénération d'adsorbants solides
EP3110790A4 (fr) Procédés et systèmes de purification de flux de déchets d'acétonitrile et procédés de synthèse d'oligonucléotides faisant appel au flux de déchets d'acétonitrile purifié
HK1257713A1 (zh) 用於蛋白純化的方法